Status:
WITHDRAWN
A Study of RO5036505 in Patients With Moderate to Severe Asthma
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma. Patients wi...
Eligibility Criteria
Inclusion
- adult patients, 18-70 years of age
- moderate to severe asthma for \>/=2 years
- ACQ score \>/= 1.5
- ICS and LABA regimen at moderate to high dose
- non-smokers
Exclusion
- oral corticosteroid use within 4 weeks prior to screening
- current escalating immunotherapy
- acute infection/antibiotic therapy within 4 weeks prior to screening, or chronic infection
- pulmonary disease other than asthma
- therapy with any approved monoclonal antibody or biologic agent within 12 months prior to screening
- previous exposure to investigational monoclonal antibodies or biologics
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00967590
Start Date
September 1 2009
End Date
August 1 2010
Last Update
August 24 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72202
2
San Diego, California, United States, 92103
3
Denver, Colorado, United States, 80206
4
Normal, Illinois, United States, 61761